Who Owns GoodRx?
GoodRx is an independent publicly traded American healthcare technology company listed on NASDAQ under the ticker symbol GDRX. Founded in 2011 by Trevor Bezdek, Doug Hirsch, and Scott Boucher, GoodRx operates as the leading platform for prescription savings in the United States, headquartered in Santa Monica, California.
Parent Company
GoodRx Holdings, Inc.
Founded
2011
Status
Publicly Traded
Headquarters
Santa Monica, California, USA
Who Owns GoodRx?
- Parent Company: GoodRx Holdings, Inc.
- Ownership Type: Public corporation
- Company Type: Publicly Traded
- Stock Ticker: Nasdaq: GDRX
| Brand | Parent Company | Ownership Type |
|---|---|---|
| GoodRx | GoodRx Holdings, Inc. | Public corporation |
History of GoodRx
- Founded: 2011
- Founders: Trevor Bezdek, Doug Hirsch, Scott Boucher
GoodRx was founded in 2011 by Trevor Bezdek, Doug Hirsch, and Scott Boucher with the mission to help Americans find affordable healthcare options. This founding vision demonstrated exceptional insight into the growing demand for healthcare technology solutions while establishing a distinctive approach that would define the healthcare category for generations. The platform was created to provide transparency in prescription drug pricing and offer discount coupons to reduce medication costs. This strategic positioning demonstrated GoodRx's exceptional ability to create differentiated healthcare solutions while maintaining consistent brand positioning and quality standards that would define the brand for decades.
The company quickly gained popularity by providing consumers with easy access to prescription drug prices at local pharmacies and discount coupons that could significantly reduce out-of-pocket costs. This period of excellence demonstrated GoodRx's exceptional ability to scale operations while maintaining consistent brand positioning and quality standards across multiple healthcare segments. GoodRx expanded its services to include telehealth consultations and healthcare provider information. This strategic diversification demonstrated GoodRx's exceptional ability to serve multiple consumer segments while maintaining its core brand identity and market leadership in the healthcare pharmaceuticals industry.
GoodRx went public through an IPO in 2020, achieving significant market valuation as a healthcare technology company. This continued evolution demonstrated GoodRx's exceptional ability to maintain market relevance while adapting to changing healthcare requirements and investor preferences. In subsequent years, Cencora (then AmerisourceBergen) made strategic investments in GoodRx, eventually leading to Cencora's ownership position in the platform. This continued excellence demonstrates GoodRx's exceptional ability to maintain market leadership while adapting to changing healthcare dynamics and regulatory requirements. This strategic integration demonstrated GoodRx's exceptional ability to integrate into larger healthcare corporations while maintaining its core brand identity and cultural significance in the healthcare technology industry. This continued success represents a significant milestone in the evolution of healthcare technology and consumer-focused prescription solutions.
About GoodRx Holdings, Inc.
American healthcare company founded in 2011, known for prescription drug price comparison and discount services, headquartered in Santa Monica, California.
- Founded: 2011
- Headquarters: Santa Monica, California, USA
- Company Type: Publicly Traded
- Stock: Nasdaq: GDRX
- Revenue: approximately $800 million (FY2024)
- Employees: approximately 1,000
Where Is GoodRx Made / Based?
- Headquarters: Santa Monica, California, USA
- Manufacturing / Operations: United States
GoodRx Sustainability & Ethics
As a healthcare technology platform, GoodRx's sustainability profile focuses on data privacy, healthcare access, and ethical business practices. The company has committed to cybersecurity and data protection standards.
GoodRx does not hold cruelty-free or vegan certifications, as these certifications are not applicable to healthcare technology platforms.
GoodRx publishes information on data security and privacy practices. The company maintains compliance with healthcare data protection regulations including HIPAA.
Awards & Recognition
GoodRx has received recognition for healthcare innovation and accessibility:
- Healthcare Innovation: GoodRx has received recognition for innovation in prescription drug price transparency.
- Consumer Choice: The platform has received awards for consumer satisfaction and healthcare affordability solutions.
- Cybersecurity: GoodRx earned 2026 cybersecurity certification demonstrating commitment to data protection.
GoodRx Recalls & Controversies
Data Privacy Concerns: GoodRx has faced questions about user data privacy and how prescription information is handled. The company maintains HIPAA compliance and has implemented privacy controls.
Pharmacy Relationship Questions: Questions have been raised about GoodRx's relationships with pharmacies and how discount programs affect pharmacy profitability.
Market Valuation Decline: GoodRx's market capitalization has declined significantly from its 2020 IPO peak, reflecting competitive pressures in the healthcare technology market.
GoodRx Ownership: Pros & Cons
Advantages
- +Market leader in U.S. prescription drug price transparency and savings
- +Direct consumer access with strong brand recognition
- +Independent public company with access to capital markets
- +Expansion into telehealth and broader healthcare services
- +Technology-driven approach to healthcare affordability
Considerations
- -Significant decline in market capitalization since 2020 IPO peak
- -Dependence on pharmacy participation and discount acceptance
- -Competition from other prescription savings platforms and pharmacy programs
- -Regulatory oversight of healthcare technology and pricing information
- -Balance between consumer savings and pharmacy profitability
Frequently Asked Questions About GoodRx
Sources & Further Reading
Where to Buy
Disclosure: We may earn commission from purchasesCompetitors to GoodRx
No direct competitors found in the same category. This could be because GoodRxoperates in a unique market segment or we're still building our competitor database.
GoodRx Holdings, Inc. Stock Information
Jobs at GoodRx Holdings, Inc.
Latest News About GoodRx
Related Articles About GoodRx
View more articlesMonthly IPO Roundup: July 2026 — June's Biggest Listings
June 2026 was the most historic IPO month in market history: SpaceX priced at $135 per share on June 12, raising $75 billion in the largest IPO ever. Quantinuum raised $1.68B, INNIO priced a $2.8B deal, and Bending Spoons filed for a $20B Nasdaq listing. Full recap.
Monthly M&A Roundup: June 2026 Brand Ownership Changes
June 2026's biggest brand ownership moves: Berkshire Hathaway agreed to buy Taylor Morrison for $6.8B, GSK struck a $10.6B deal for Nuvalent, CRH acquired Arcosa for $8.5B, and Qualcomm agreed to buy AI startup Modular for $3.92B. Full breakdown of every major deal.
A Complete Guide to LVMH Brands: What Does the Luxury Giant Own?
LVMH owns 75 luxury maisons including Louis Vuitton, Dior, Tiffany, Guerlain, and Sephora. Here is the complete brand list by division, with acquisition dates and what each brand does.
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Accutane
Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.

Activase
Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.

Acuvue
Acuvue is the world's leading contact lens brand, owned by Johnson & Johnson Vision Care, a division of Johnson & Johnson. The brand covers daily, weekly, and monthly disposable soft contact lenses sold in more than 100 countries.